Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

Kim SP, et al.
Cancer Immunology Research
August 2022
Authors and Affiliates
Sanghyun P Kim 1, Nolan R Vale 1, Nikolaos Zacharakis 1, Sri Krishna 1, Zhiya Yu 1, Billel Gasmi 2, Jared J Gartner 1, Sivasish Sindiri 1, Parisa Malekzadeh 1, Drew C Deniger 1, Frank J Lowery 1, Maria R Parkhurst 1, Lien T Ngo 1, Satyajit Ray 1, Yong F Li 1, Victoria Hill 1, Maria Florentin 1, Robert V Masi 1, Biman C Paria 1, Noam Levin 1, Alakesh Bera 1, Elizabeth A Hedges 1, Agnes Choi 1, Praveen D Chatani 1, Anup Y Parikh 1, Shoshana Levi 1, Samantha Seitter 1, Yong-Chen Lu 1, Zhili Zheng 1, Todd D Prickett 1, Li Jia 3, Jonathan M Hernandez 4, Chuong D Hoang 5, Paul F Robbins 1, Stephanie L Goff 1, Richard M Sherry 1, James C Yang 1, Steven A Rosenberg 1; 1 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2 Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland. 3 National Institutes of Health Library, Office of Director, National Institutes of Health, Bethesda, Maryland. 4 Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 5 Thoracic Surgery Branch, National Cancer Institute, NIH, CCR and The Clinical Center, Bethesda, Maryland.

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling

Fix SM, et al.
Journal for ImmunoTherapy of Cancer
August 2022
Authors and Affiliates
Samantha M Fix 1, Marie-Andrée Forget 1, Donastas Sakellariou-Thompson 1, Yunfei Wang 1, Tamara M Griffiths 2, Minjung Lee 3, Cara L Haymaker 3, Ana Lucía Dominguez 1, Rafet Basar 4, Christopher Reyes 5, Sanjay Kumar 5, Larissa A Meyer 6, Patrick Hwu #,7, Chantale Bernatchez #,1, Amir A Jazaeri #,6; 1 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2 Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3 Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 4 Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5 Cell Biology R&D, Thermo Fisher Scientific, Carlsbad, California, USA. 6 Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 7 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Patrick.Hwu@moffitt.org. # Contributed equally.

BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma

Kremenovic M, et al.
Journal for ImmunoTherapy of Cancer
August 2022
Authors and Affiliates
Mirela Kremenovic 1,2, Alfred A Chan 3, Bing Feng 4, Lukas Bäriswyl 1, Steve Robatel 1,2, Thomas Gruber 1, Li Tang 4, Delphine J Lee 3, Mirjam Schenk 5; 1 Experimental Pathology, University of Bern Institute of Pathology, Bern, Switzerland. 2 Graduate School Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. 3 Division of Dermatology, Department of Medicine, The Lundquist Institute, Torrance, California, USA. 4 Institute of Bioengineering and Institute of Materials Science and Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, VD, Switzerland. 5 Experimental Pathology, University of Bern Institute of Pathology, Bern, Switzerland mirjam.schenk@pathology.unibe.ch.

High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments

Fernandez N, et al.
August 2022
Authors and Affiliates
Nicolas Fernandez 1, Deepak Perumal 2, Adeeb Rahman 3, Seunghee Kim-Schulze 3, Jen Yesil 4, Daniel Auclair 4, Homer Adams 3rd 5, Samir Parekh 6, Sacha Gnjatic 7, Hearn Jay Cho 8; 1 Precision Immunology Institute. 2 Tisch Cancer Institute. 3 Human Immune Monitoring Center. 4 Multiple Myeloma Research Foundation, Norwalk, CT. 5 Janssen Research & Development, LLC, Spring House, PA. 6 Precision Immunology Institute; Tisch Cancer Institute; Department of Oncological Sciences, Icahn School of Medicine at Mt. Sinai, New York, NY. 7 Precision Immunology Institute; Tisch Cancer Institute; Human Immune Monitoring Center. 8 Precision Immunology Institute; Tisch Cancer Institute; Multiple Myeloma Research Foundation, Norwalk, CT. Electronic address: hearn.jay.cho@mssm.edu.

Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.

Taranto E, et al.
August 2022
Authors and Affiliates
Eleanor Tarantoa, Robert Reddb, Erin Jeterc, Kristin McHughc, Jennifer L. Crombiec, David C. Fisherc,Eric Jacobsenc, Caron A. Jacobsonc, Austin I. Kimc, Ann S. LaCascec, Oreofe O. Odejidec, Parastoo B. Dahid,Yago Nietoe, Robin M. Joycef, Yi-Bin Cheng, Kimberley-Jane C. Bonjoch, Ammar Chaudhryh,Alex F. Herrerah, Philippe Armandc and Reid W. Merrymanc aDepartment of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; bDepartment of Data Sciences, Dana-Farber CancerInstitute, Boston, MA, USA; cDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA; d Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; eDepartment of StemCell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; fDepartment of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USA; gHematopoietic Cell Therapy and Transplant Program, Massachusetts General Hospital, Boston, MA, USA; hDepartment of Hematology and Hematopoietic Cell Transplantation,City of Hope National Medical Center, Duarte, CA, USA

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.

Wang M, et al.
Journal of Clinical Oncology
June 2022
Authors and Affiliates
Michael Wang, MD1; Javier Munoz, MD, MS, MBA2; Andre Goy, MD, MS3; Frederick L. Locke, MD4; Caron A. Jacobson, MD, MMSc5;Brian T. Hill, MD, PhD6; John M. Timmerman, MD7; Houston Holmes, MD, MBA8; Samantha Jaglowski, MD9; Ian W. Flinn, MD, PhD10;Peter A. McSweeney, MB, ChB11; David B. Miklos, MD, PhD12; John M. Pagel, MD, PhD, DSc13; Marie Jose Kersten, MD, PhD ´ 14;Krimo Bouabdallah, MD15; Rashmi Khanal, MD16; Max S. Topp, MD17; Roch Houot, MD, PhD18; Amer Beitinjaneh, MD19;Weimin Peng, PhD20; Xiang Fang, PhD20; Rhine R. Shen, PhD20; Rubina Siddiqi, PhD20; Ioana Kloos, MD20; and Patrick M. Reagan, MD21 1The University of Texas MD Anderson Cancer Center, Houston, TX 2Banner MD Anderson Cancer Center, Gilbert, AZ 3John Theurer Cancer Center, Hackensack University, Hackensack, NJ 4Moffitt Cancer Center, Tampa, FL 5Dana-Farber Cancer Institute, Boston, MA 6Cleveland Clinic Foundation, Cleveland, OH 7David Geffen School of Medicine at UCLA, Los Angeles, CA 8Texas Oncology, Dallas, TX 9The Ohio State University Comprehensive Cancer Center, Columbus, OH 10Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 11Colorado Blood Cancer Institute, Denver, CO 12Stanford University School of Medicine, Stanford, CA 13Swedish Cancer Institute, Seattle, WA 14Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, the Netherlands, on behalf of HOVON/LLPC 15CHU Bordeaux, Service d’Hematologie et th ´ erapie Cellulaire, ´Bordeaux, France 16Fox Chase Cancer Center, Philadelphia, PA 17Medizinische Klinik und Poliklinik II, Universitatsklinikum W ¨ urzburg, ¨Wurzburg, Germany ¨ 18CHU Rennes, Universite Rennes, INSERM & EFS, Rennes, France ´ 19University of Miami, Miami, FL 20Kite, a Gilead Company, Santa Monica, CA 21University of Rochester Medical Center, Rochester, NY

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant

Gottlieb DJ, et al.
American Journal of Hematology
May 2022
Authors and Affiliates
David J Gottlieb 1,2,3,4, Gaurav Sutrave 1,2,4, Wei Jiang 1,2, Selmir Avdic 2,4, Janine A Street 2,4, Renee Simms 1,2, Leighton E Clancy 1,4,5, Vicki Antonenas 5, Brian S Gloss 6, Caroline Bateman 2,4,7, David C Bishop 1,2,4, Kenneth P Micklethwaite 1,2,3,5, Emily Blyth 1,2,3,4; 1 Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales. 2 Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales. 3 Department of Haematology, Westmead Hospital, Sydney, New South Wales. 4 T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales. 5 Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead, New South Wales, Australia. 6 Westmead Research Hub, Westmead Institute for Medical Research, Sydney, New South Wales, Australia. 7 Departments of Haematology and Oncology, Children's Hospital at Westmead, Sydney, New South Wales, Australia.

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Narayan V, et al.
Nature Medicine
May 2022
Authors and Affiliates
Vivek Narayan 1,2, Julie S Barber-Rotenberg 3, In-Young Jung #,2,3,4, Simon F Lacey #,3,5, Andrew J Rech #,2,3,5,6, Megan M Davis #,3, Wei-Ting Hwang 7, Priti Lal 2,5, Erica L Carpenter 2,6, Shannon L Maude 8,9, Gabriela Plesa 3, Neha Vapiwala 1,2, Anne Chew 3, Michael Moniak 3, Ronnie A Sebro 2,10, Michael D Farwell 2,10, Amy Marshall 3, Joan Gilmore 3, Lester Lledo 3, Karen Dengel 3, Sarah E Church 11, Tyler D Hether 11, Jun Xu 3, Mercy Gohil 3, Thomas H Buckingham 2,6, Stephanie S Yee 2,6, Vanessa E Gonzalez 3, Irina Kulikovskaya 3, Fang Chen 3, Lifeng Tian 3, Kyle Tien 2,6, Whitney Gladney 3, Christopher L Nobles 4, Hayley E Raymond 4, Prostate Cancer Cellular Therapy Program Investigators; Elizabeth O Hexner 1,2,3, Donald L Siegel 3,5, Frederic D Bushman 4, Carl H June #,12,13,14,15, Joseph A Fraietta #,16,17,18,19,20, Naomi B Haas #,21,22; 1 Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 6 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA. 7 Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 8 Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 9 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 10 Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 11 NanoString Technologies, Inc., Seattle, WA, USA. 12 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 13 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 14 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 15 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 16 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 17 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 18 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 19 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 20 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 21 Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. naomi.haas@pennmedicine.upenn.edu. 22 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. naomi.haas@pennmedicine.upenn.edu. # Contributed equally.

A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

Wagner MJ, et al.
Clinical Cancer Research
May 2022
Authors and Affiliates
Michael J Wagner 1, Yuzheng Zhang 2, Lee D Cranmer 1, Elizabeth T Loggers, Graeme Black 3, Sabrina McDonnell 4, Shannon Maxwell 5, Rylee Johnson 5, Roxanne Moore 1, Pedro Hermida de Viveiros 6, Lauri Aicher 4, Kimberly S Smythe 4, Qianchuan He 3, Robin L Jones 7, Seth M Pollack 6; 1 University of Washington, Seattle, WA, United States. 2 Fred Hutchinson Cancer Research Center, Seattle, United States. 3 Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 4 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States. 5 Seattle Cancer Care Alliance, Seattle, United States. 6 Northwestern University, Chicago, IL, United States. 7Royal Marsden Hospital / Institute of Cancer Research, London, Chelsea, United Kingdom.